QRxPharma announced results from its exploratory Phase 3 study of MoxDuo IR for the treatment of moderate to severe postoperative pain following bunionectomy surgery. This double-blind, randomized, fixed-dose trial enrolled 375 patients investigating the primary endpoint of respiratory depression as measured by oxygen desaturation–an opioid-related adverse event–was less severe and of shorter duration in patients receiving MoxDuo 12mg/8mg compared to those receiving equianalgesic doses of either morphine 24mg or oxycodone 16mg alone. In this study, measures of insufficient blood oxygenation (oxygen desaturation SpO2<90%) over time to assess both the severity and duration of respiratory impairment indicated that MoxDuo has a significantly better (P<0.02) safety profile than oxycodone.  Beneficial trends for MoxDuo also occurred in comparisons to morphine treatment on these same endpoints.

MoxDuo IR comes in a capsule formulation in a 3:2 fixed ratio combination of morphine and oxycodone.

For more information call (908) 506-2900 or visit www.qrxpharma.com.